Jeroen Hiltermann

Pulmonologist Profile

Pulmonologist

Contact information

- Efficacy and Safety of Rilvegostomig (Anti-PD-1/TIGIT) in Checkpoint Inhibitor-Naïve Metastatic NSCLC: ARTEMIDE-01 (Speaker), Jeroen Hiltermann (Contributor) 28-Mar-2026 Academic presentation > Academic
- Efficacy and safety of rilvegostomig, an anti-PD-1/TIGIT bispecific antibody, for checkpoint inhibitor (CPI)-naïve metastatic non-small-cell lung cancer (mNSCLC): ARTEMIDE-01 (Speaker), Jeroen Hiltermann (Contributor) 20-Oct-2025 Academic presentation > Academic
- Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific, for CPI-naïve Metastatic NSCLC with PD-L1 1–49% or ≥50% (Speaker), Jeroen Hiltermann (Contributor) 7-Mar-2025 Academic presentation > Academic
- Interim analysis of a randomized study of 1L BMS-986012 (anti-fucosyl-GM-1) with Chemotherapy and nivolumab in ES-SCLC (Speaker), Jeroen Hiltermann (Contributor) 6-Mar-2025 Academic presentation > Academic
- Lectures at EMMP Module 7 ImmunopathologyJeroen Hiltermann (Speaker) 12-Feb-2025 Professional or public presentation > Professional
All activities
- TLCR Outstanding AuthorJeroen Hiltermann, Mar-2025 Academic
All prizes

Part of

TRIGR - Translational Immunology Groningen | Programme

Contact